Bluejay Diagnostics, Inc. (BJDX)
| Market Cap | 1.11M -49.6% |
| Revenue (ttm) | n/a |
| Net Income | -6.90M |
| EPS | -10.45 |
| Shares Out | 1.03M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 760,683 |
| Open | 1.150 |
| Previous Close | 1.150 |
| Day's Range | 1.050 - 1.150 |
| 52-Week Range | 0.830 - 16.680 |
| Beta | 0.89 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 13, 2026 |
About BJDX
Bluejay Diagnostics, Inc. operates as a medical diagnostics company. It offers Symphony technology platform which consists of an analyzer and single-use protein detection cartridges that are designed to provide measurements of key diagnostic biomarkers found in blood; and Symphony analyzer used to orchestrate sample processing of whole blood, plasma, serum, etc., biomarker isolation, and immunoassay preparation using non-contact centrifugal force. The company also develops Symphony IL-6 tests for the monitoring of disease progression in critica... [Read more]
Financial Performance
Financial StatementsNews
Bluejay Diagnostics completes enrollment in SYMON-II study
Bluejay Diagnostics (BJDX) announced the successful completion of patient enrollment in its SYMON-II multicenter clinical validation study. The study achieved its targeted enrollment of 750 patients e...
Bluejay Diagnostics Announces Successful Completion of Enrollment in the SYMON-II Multicenter Clinical Validation Study
750 Patients Enrolled Ahead of Plan in Pivotal Study Evaluating Symphony™ IL-6 for Early Assessment of 28-Day Sepsis Mortality Risk 750 Patients Enrolled Ahead of Plan in Pivotal Study Evaluating Symp...
Bluejay Diagnostics files to sell 11.22M shares of common stock for holders
17:21 EDT Bluejay Diagnostics (BJDX) files to sell 11.22M shares of common stock for holders
Bluejay Diagnostics Announces Closing of Up to $23.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules
$8.5 million upfront with up to approximately $15.2 million of potential additional gross proceeds upon the exercise in full of warrants
Bluejay Diagnostics Announces up to $23.6 Million Private Placement Priced At-the-Market Under Nasdaq Rules
$8.5 million upfront with up to approximately $15.1 million of potential additional gross proceeds upon the exercise in full of warrants
Why Is Penny Stock Bluejay Diagnostics (BJDX) Up Today?
Bluejay Diagnostics stock was up after the company announced a new strategic partnership.
Bluejay Diagnostics, Argonaut Manufacturing Services announce partnership
Bluejay Diagnostics (BJDX) announced a strategic partnership with Argonaut Manufacturing Services to support the advancement of Bluejay’s Symphony platform. This partnership is designed to support Blu...
Bluejay Diagnostics and Argonaut Manufacturing Services Announce Strategic Partnership
ACTON, Mass. and CARLSBAD, Calif., June 02, 2026 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (“Bluejay” or the “Company”) (NASDAQ: BJDX), a medical diagnostics company focused on near-patient testin...
Bluejay Diagnostics Provides First Quarter 2026 Corporate Update
ACTON, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (“Bluejay” or the “Company”), a medical diagnostics company focused on improving patient outcomes in critical care settings, to...
Bluejay Diagnostics reaches 624 patient enrollment in Symphony clinical trial
Bluejay Diagnostics (BJDX) announced the enrollment of 624 patients in its ongoing SYMON-II Trial, a pivotal clinical study evaluating the company’s Symphony platform for interleukin-6 testing in crit...
Bluejay Diagnostics, Inc. Announces Completion of 624 Patient Enrollments in SYMON-II Pivotal Clinical Trial
ACTON, Mass., April 07, 2026 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (“Bluejay” or the “Company”), a medical diagnostics company focused on rapid, near-patient testing, today announced the succe...
Bluejay Announces Abstract Accepted for Presentation at the 2026 Society of Academic Emergency Medicine (SAEM) Annual Meeting
New clinical data from the SYMON-I study to evaluate IL-6 and organ dysfunction in sepsis patients to be presented. New clinical data from the SYMON-I study to evaluate IL-6 and organ dysfunction in s...
NorthStrive Fund urges Bluejay to evaluate strategic opportunity
NorthStrive Fund II issued an open letter to the Board of Directors and shareholders of Bluejay Diagnostics (BJDX), recommending the Board evaluate a strategic opportunity that NorthStrive believes co...
NorthStrive Fund II LP Issues Open Letter to the Board and Shareholders of Bluejay Diagnostics
NEWPORT BEACH, Calif., March 11, 2026 (GLOBE NEWSWIRE) -- NorthStrive Fund II LP (“NorthStrive Fund”), a subsidiary of NorthStrive Companies Inc., today issued an open letter to the Board of Directors...
Bluejay Diagnostics says SYMON II study ‘progressing as planned’
Bluejay continues to advance its Symphony platform, including the company’s lead product candidate for the rapid measurement of Interleukin-6 to support sepsis risk assessment and critical-care decisi...
Bluejay Diagnostics Announces All Prefunded Warrants Now Exercised
ACTON, Mass., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Bluejay Diagnostics (NASDAQ: BJDX) today announced that as of February 19, 2026, all of the prefunded warrants issued by the Company in its October 2025...
Bluejay Diagnostics enrolls 545 patients in SYMON II study
Bluejay Diagnostics (BJDX) announced that it has successfully enrolled 545 patients in its SYMON II multicenter clinical study and has made substantial progress in advancing manufacturing readiness an...
Bluejay Diagnostics Successfully Enrolls 545 Patients in SYMON™ II Study and Advances Manufacturing Readiness into 2026
ACTON, Mass., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Bluejay Diagnostics (NASDAQ: BJDX) today announced that it has successfully enrolled 545 patients in its SYMON™ II multicenter clinical study and has ma...
Bluejay Diagnostics Inc trading halted, news pending
19:50 EST Bluejay Diagnostics (BJDX) Inc trading halted, news pending
Bluejay Diagnostics announces 1-for-4 reverse stock split
Bluejay Diagnostic announced that the Company’s Board of Directors has approved a reverse stock split of its shares of common stock at a ratio of 1-for-4. The Reverse Stock Split…
Bluejay Diagnostics completes commercial-scale IL-6 antibody production
Bluejay Diagnostics (BJDX) completed commercial-scale production of both polyclonal and monoclonal antibodies targeting interleukin-6, a biomarker relevant to inflammatory and critical-care applicatio...
Bluejay Diagnostics Announces Completion of Commercial-Scale IL-6 Antibody Production
ACTON, Mass., Dec. 29, 2025 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”) announced that it has completed commercial-scale production of both polyclonal and...
Bluejay Diagnostics provides Q3 corporate update
Third Quarter 2025 and Recent Corporate Highlights: SYMON-II Pivotal Clinical Study Continues: Bluejay continues patient enrollment in the SYMON-II pivotal clinical trial, designed to validate finding...
Bluejay Diagnostics files to sell 6.93M shares of common stock for holders
The company is not selling any shares of common stock under this prospectus and will not receive any proceeds from the sale of shares of common stock by the selling…
Bluejay Diagnostics Announces Closing of $4.5 Million Private Placement Priced At-The-Market Under Nasdaq Rules
ACTON, Mass., Oct. 10, 2025 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical diagnostics company developing near-patient solutions for critical care...